Oppenheimer & Co’s MetLife MET Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.66M Sell
31,455
-137
-0.4% -$11K 0.03% 559
2026
Q1
$2.23M Sell
31,592
-425
-1% -$31.8K 0.03% 554
2025
Q4
$2.53M Sell
32,017
-607
-2% -$48K 0.04% 476
2025
Q3
$2.69M Sell
32,624
-329
-1% -$25.9K 0.03% 517
2025
Q2
$2.65M Sell
32,953
-1,324
-4% -$102K 0.04% 500
2025
Q1
$2.75M Buy
34,277
+4,536
+15% +$377K 0.04% 462
2024
Q4
$2.44M Buy
29,741
+1,249
+4% +$104K 0.04% 492
2024
Q3
$2.35M Sell
28,492
-124
-0.4% -$9.26K 0.04% 501
2024
Q2
$2.01M Buy
28,616
+954
+3% +$68.1K 0.03% 532
2024
Q1
$2.05M Buy
27,662
+477
+2% +$33.2K 0.03% 505
2023
Q4
$1.8M Buy
27,185
+36
+0.1% +$2.25K 0.03% 525
2023
Q3
$1.71M Sell
27,149
-22,295
-45% -$1.39M 0.04% 510
2023
Q2
$2.8M Sell
49,444
-445
-0.9% -$24.7K 0.06% 389
2023
Q1
$2.89M Buy
49,889
+1,670
+3% +$113K 0.06% 352
2022
Q4
$3.49M Sell
48,219
-1,202
-2% -$86.1K 0.08% 295
2022
Q3
$3M Sell
49,421
-11,041
-18% -$705K 0.07% 325
2022
Q2
$3.8M Buy
60,462
+2,204
+4% +$146K 0.08% 285
2022
Q1
$4.09M Buy
58,258
+21,268
+57% +$1.44M 0.07% 318
2021
Q4
$2.31M Sell
36,990
-438
-1% -$27.5K 0.04% 476
2021
Q3
$2.31M Sell
37,428
-2,394
-6% -$144K 0.04% 463
2021
Q2
$2.38M Sell
39,822
-259
-0.6% -$16.4K 0.04% 458
2021
Q1
$2.44M Sell
40,081
-971
-2% -$53.6K 0.05% 407
2020
Q4
$1.93M Sell
41,052
-398
-1% -$17.2K 0.04% 449
2020
Q3
$1.54M Buy
41,450
+5,352
+15% +$203K 0.04% 452
2020
Q2
$1.32M Sell
36,098
-35,966
-50% -$1.25M 0.03% 480
2020
Q1
$2.2M Buy
72,064
+22,093
+44% +$980K 0.07% 319
2019
Q4
$2.55M Sell
49,971
-3,214
-6% -$155K 0.06% 349
2019
Q3
$2.51M Sell
53,185
-28,616
-35% -$1.36M 0.07% 332
2019
Q2
$4.06M Sell
81,801
-12,897
-14% -$606K 0.11% 213
2019
Q1
$4.03M Sell
94,698
-15,653
-14% -$692K 0.11% 217
2018
Q4
$4.53M Sell
110,351
-6,488
-6% -$278K 0.14% 157
2018
Q3
$5.46M Sell
116,839
-31,053
-21% -$1.42M 0.14% 174
2018
Q2
$6.45M Sell
147,892
-6,589
-4% -$307K 0.18% 131
2018
Q1
$7.09M Sell
154,481
-131,229
-46% -$6.37M 0.18% 130
2017
Q4
$14.4M Sell
285,710
-1,247
-0.4% -$65.7K 0.37% 58
2017
Q3
$14.9M Sell
286,957
-45,630
-14% -$2.22M 0.4% 53
2017
Q2
$16.3M Sell
332,587
-9,220
-3% -$428K 0.45% 42
2017
Q1
$16.1M Sell
341,807
-23,613
-6% -$1.13M 0.46% 43
2016
Q4
$17.6M Sell
365,420
-25,647
-7% -$1.18M 0.51% 35
2016
Q3
$15.5M Buy
391,067
+3,377
+0.9% +$127K 0.45% 50
2016
Q2
$13.8M Buy
387,690
+11,803
+3% +$460K 0.41% 54
2016
Q1
$14.7M Buy
375,887
+56,865
+18% +$2.13M 0.45% 47
2015
Q4
$13.7M Buy
319,022
+1,235
+0.4% +$54.3K 0.41% 52
2015
Q3
$13.4M Sell
317,787
-6,838
-2% -$319K 0.41% 47
2015
Q2
$16.2M Buy
324,625
+70,155
+28% +$3.32M 0.45% 43
2015
Q1
$11.5M Sell
254,470
-7
-0% -$315 0.31% 69
2014
Q4
$12.3M Buy
254,477
+1,987
+0.8% +$94.4K 0.35% 59
2014
Q3
$12.1M Buy
252,490
+129,182
+105% +$6.27M 0.36% 50
2014
Q2
$6.11M Sell
123,308
-80,209
-39% -$3.75M 0.18% 129
2014
Q1
$9.58M Sell
203,517
-27,632
-12% -$1.27M 0.29% 72
2013
Q4
$11.1M Sell
231,149
-105,923
-31% -$4.75M 0.36% 54
2013
Q3
$14.1M Sell
337,072
-4,250
-1% -$183K 0.5% 34
2013
Q2
$13.9M Buy
+341,322
New +$12.6M 0.54% 31

Other funds holding MET

Oppenheimer & Co's MET Position: Q2 2026 in Review

Oppenheimer & Co reduced its MetLife (MET) stake by 0.43% in Q2 2026, selling an estimated $11K and leaving 31,455 shares worth $2.66M. The position accounts for 0.03% of the portfolio, ranked #559.

Oppenheimer & Co first reported a position in MET in Q2 2013 and has held it in 53 quarters since. The position peaked at $17.6M in Q4 2016. 1,445 funds tracked by Wall St. Rank hold MET as of Q2 2026.

  • Oppenheimer & Co held 31,455 shares of MetLife worth $2.66M as of Q2 2026.
  • Oppenheimer & Co sold 137 MetLife shares in Q2 2026, an estimated $11K.
  • MetLife made up 0.03% of Oppenheimer & Co's portfolio in Q2 2026, its #559 holding.
  • Oppenheimer & Co first reported a position in MetLife in Q2 2013 and has held it in 53 quarters since.
  • Oppenheimer & Co's MetLife position peaked at $17.6M in Q4 2016.
  • 1,445 funds tracked by Wall St. Rank held MetLife as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.